Relaxo Footwears Ltd
RELAXORelaxo Footwears Ltd is coiled. The quarters are improving, yet the P/E sits at the 5th percentile of its own 11-year range — the business is moving before the market.
The sharpest disagreement: annual EPS moved +5.3% against a −33.6% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (6 weeks in) while the P/E sits at the 5th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +12.2% year on year, and 180% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Relaxo Footwears Ltd trades at ₹325, in a confirmed uptrend and 6 weeks into that stage. That is −13.6% against its own 200-day average. It sits at 40% of a 52-week range of ₹250 to ₹440. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a confirmed uptrend — week 6 of stage 2, confirmed. At ₹325 it trades −13.6% versus its 200-day average and sits at 40% of its 52-week range (₹250–₹440).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +68% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-08-21) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Relaxo Footwears Ltd trades at 43.6× P/E, near the bottom of its own range — cheaper only 5% of the time. Its long-run median P/E is 67.1×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 43.6× is near the bottom of its own range — cheaper only 5% of the time, against a long-run median of 67.1× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +5.3% against a −33.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −22.7%/yr price move, ~−9.1%/yr came from earnings growth and ~−13.6 pp from the multiple (compressing); over 10y, of the +4.1%/yr price move, ~+4.2%/yr came from earnings growth and ~−0.1 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Relaxo Footwears Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 5 quarters ago at −13.4% and has held its recovery at +6.3%, ROCE holding at 11.1%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −3.2% | −1.0% | +2.8% | +4.9% |
| Profit | +5.3% | +5.1% | −9.3% | +4.1% |
| EPS | +5.3% | +5.1% | −9.3% | +3.7% |
| Share price | −33.6% | −29.4% | −22.7% | +4.1% |
4-Factor Sector Score
30.1/100 — rank 7 of 7 in Footwear · 100% evidence confidence
Relaxo Footwears Ltd scores 30.1 out of 100 against the 7 companies it is compared with in Footwear, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 13.3 + 11.6 + 2.9 + 2.3 = 30.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Relaxo Footwears Ltd reported ₹705 Cr of revenue in the Jun 26 quarter, +7.8% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 4.9% a year. The last full year, FY26, came in at ₹2,702 Cr. The last four reported quarters add to ₹2,753 Cr.
FY26 revenue came in at ₹2,702 Cr (−3.2% on the year), capping 10 years at 4.9% compound. The latest quarter (Jun 26) printed ₹705 Cr, +7.8% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +2.1% growth against the decade's 4.9% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +2.2% over the last 4 quarters against −3.0%/yr over the last 8 — accelerating; TTM profit +6.3% vs −0.5%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Relaxo Footwears Ltd's operating margin is 15.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 15.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0%–21.0%.
Why the margin moved: operating margin went +0.2 pp year on year while gross margin went +4.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Relaxo Footwears Ltd earned ₹55.0 Cr of net profit in the Jun 26 quarter, +12.2% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹179 Cr. The 10-year compound rate is 4.1%. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹49.0 Cr.
Jun 26 profit was ₹55.0 Cr, +12.2% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹179 Cr (+5.3%), and the 10-year compound rate is 4.1%.
Why profit moved: revenue contributed +7.8% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +3.2% vs revenue +2.1%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 180% of Relaxo Footwears Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹348 Cr of operating cash against ₹179 Cr of profit. After ₹221 Cr of capital spending, ₹127 Cr was left as free cash.
FY26: operating cash of ₹348 Cr against reported profit of ₹179 Cr, leaving free cash of ₹127 Cr after ₹221 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 180% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 180%: the cash cycle stretched 37 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Relaxo Footwears Ltd's cash conversion cycle runs 138 days in FY26, up from 101 days in FY21. Capital spending ran ₹685 Cr over the last 3 years. At FY26 sales of ₹2,702 Cr each day of that cycle holds about ₹7.4 Cr, so roughly ₹1,022 Cr sits inside the business at any moment.
FY26: debtors at 40 days, inventory at 184 days — roughly 6.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 138 days, looser than FY21's 101.
The full loop: cash goes out to suppliers and production on day 0; stock waits 184 days to sell; customers pay about 40 days after that; and suppliers themselves are paid at 87 days — netting out to the 138-day cycle.
In money terms: at FY26 sales of ₹2,702 Cr, each day of the cycle holds about ₹7.4 Cr — so the 138-day loop keeps roughly ₹1,022 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹685 Cr over the last 3 fiscal years against ₹462 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹97.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Relaxo Footwears Ltd earns a ROCE of 11% in FY26. Return on invested capital clears the cost of that capital by −4.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.6% net margin on 0.92× asset turns.
FY26 ROCE is 11%.
🚨 Why the return is what it is — the wiring (FY26): 6.6% net margin × 0.92× asset turns × 1.34× balance-sheet leverage ≈ 8.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 7.5% − 12.0% = a −4.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Relaxo Footwears Ltd carries total debt of ₹233 Cr against shareholder equity of ₹2,206 Cr as of Mar 26, a debt-to-equity of 0.11 — effectively unlevered. On the annual view that ratio went from 0.10 in FY22 to 0.11 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹233 Cr against shareholder equity of ₹2,206 Cr — a debt-to-equity of 0.11. On the annual view, debt-to-equity went from 0.10 (FY22) to 0.11 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Relaxo Footwears Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.1 points over the same window, to 9.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.3 points over 8 quarters to 3.1%; Domestic institutions: +0.1 points over 8 quarters to 9.7%; Promoters: +0.0 points over 8 quarters to 71.3%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Relaxo Footwears Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Redtape LtdREDTAPE | 69.3/100Favorable setup100% evidence | ASLEEP | 27.9/35 Revenue 19% · PAT 38.8% · OPM change 0 pp 100% evidence | 18.0/25 ROCE 24.5% · OPM 17% 100% evidence | 18.9/20 P/E 26× · PEG 0.76 100% evidence | 4.5/20 RS sector -8.4% · RS bench -8.8% · 1Y -20.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 18 + 18.9 + 4.5 = 69.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.4% and the one-year return is -20.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 2Sreeleathers LtdSREEL | 63.0/100Mixed-positive evidence72% evidence | BREAKING OUT | 27.9/35 Revenue 16.7% · PAT 56.9% · OPM change 7 pp 95% evidence | 10.6/25 ROCE 7% · OPM 14.9% 95% evidence | 12.0/20 P/E 23.5× · PEG — 50% evidence | 12.5/20 RS sector — · RS bench 57.2% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 27.9 + 10.6 + 12 + 12.5 = 63 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Campus Activewear LtdCAMPUS | 60.4/100Mixed-positive evidence94% evidence | BASING | 21.8/35 Revenue 13.8% · PAT 31.6% · OPM change 0 pp 100% evidence | 14.4/25 ROCE 21.2% · OPM 14% 100% evidence | 11.7/20 P/E 42.5× · PEG 2.04 100% evidence | 12.5/20 RS sector 12.1% · RS bench -13.1% · 1Y -21.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.8 + 14.4 + 11.7 + 12.5 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Metro Brands LtdMETROBRAND | 50.6/100Mixed-positive evidence94% evidence | BASING | 14.6/35 Revenue 15.5% · PAT 14.1% · OPM change -1 pp 100% evidence | 18.6/25 ROCE 20.1% · OPM 30% 100% evidence | 4.9/20 P/E 63.1× · PEG 4 100% evidence | 12.5/20 RS sector 7.3% · RS bench -10.2% · 1Y -23.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 18.6 + 4.9 + 12.5 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 5Mirza International LtdMIRZAINT | 33.4/100Adverse evidence72% evidence | 9.7/35 Revenue -9.3% · PAT 100% · OPM change -6.7 pp 95% evidence | 3.4/25 ROCE -1.8% · OPM 2.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.3/20 RS sector -4.8% · RS bench -7.6% · 1Y -1.2%4 of 7 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 9.7 + 3.4 + 10 + 10.3 = 33.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Bata India LtdBATAINDIA | 32.4/100Adverse evidence84% evidence | ASLEEP | 8.1/35 Revenue 1.9% · PAT -30.1% · OPM change 0 pp 100% evidence | 13.0/25 ROCE 12.7% · OPM 21% 100% evidence | 8.3/20 P/E 48× · PEG — 50% evidence | 3.0/20 RS sector -20.9% · RS bench -21.2% · 1Y -47.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.1 + 13 + 8.3 + 3 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Relaxo Footwears Ltdthis pageRELAXO | 30.1/100Adverse evidence100% evidence | ASLEEP | 13.3/35 Revenue 2.1% · PAT 6.3% · OPM change 0 pp 100% evidence | 11.6/25 ROCE 11.2% · OPM 15% 100% evidence | 2.9/20 P/E 43.6× · PEG 6.15 100% evidence | 2.3/20 RS sector -10.3% · RS bench -11.2% · 1Y -34.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 11.6 + 2.9 + 2.3 = 30.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Relaxo Footwears Ltd's share price today?
Relaxo Footwears Ltd trades at ₹325, −33.6% over the past year. The company is valued at ₹8,089 Cr. The stock sits at 40% of its 52-week range of ₹250–₹440, −13.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 6 weeks in. — as of 11 September 2026.
What were Relaxo Footwears Ltd's latest quarterly results?
Relaxo Footwears Ltd reported revenue of ₹705 Cr and net profit of ₹55.0 Cr for the Jun 26 quarter. Revenue rose 7.8% and profit rose 12.2% year on year. Earnings per share were ₹2.21. The operating margin was 15.0%, 0.0 pp higher than a year earlier. — as of 11 September 2026.
What is Relaxo Footwears Ltd's revenue?
Relaxo Footwears Ltd reported revenue of ₹705 Cr in the Jun 26 quarter, +7.8% year on year. For the full FY26 fiscal year, revenue was ₹2,702 Cr (−3.2%). Over the last 10 years revenue compounded at 4.9% a year. — as of 11 September 2026.
What is Relaxo Footwears Ltd's profit?
Relaxo Footwears Ltd earned ₹55.0 Cr of net profit in the Jun 26 quarter, +12.2% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹179 Cr. The operating margin ran 15.0% in the latest quarter. — as of 11 September 2026.
What is Relaxo Footwears Ltd's market cap?
Relaxo Footwears Ltd's market capitalisation is ₹8,089 Cr at a share price of ₹325. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Relaxo Footwears Ltd's P/E ratio?
Relaxo Footwears Ltd trades at a P/E of 43.6×, at the 5th percentile of its own 11-year range, against a long-run median of 67.1×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Relaxo Footwears Ltd pay a dividend?
Yes — Relaxo Footwears Ltd's dividend payout was 49% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Relaxo Footwears Ltd overvalued?
On its own history, Relaxo Footwears Ltd looks cheap: its P/E of 43.6× has been cheaper only 5% of the time in 11 years (long-run median 67.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Relaxo Footwears Ltd growing?
Yes — Relaxo Footwears Ltd is growing: latest-quarter revenue +7.8% year on year, profit +12.2%, and the margin +0.0 pp at 15.0%. The 10-year compound rates are 4.9% (revenue) and 4.1% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Relaxo Footwears Ltd performing?
Relaxo Footwears Ltd is in a confirmed uptrend, 6 weeks in. Its latest quarter's revenue rose 7.8% and profit rose 12.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Relaxo Footwears Ltd in?
Improving — profit growth bottomed 5 quarters ago at −13.4% and has held its recovery at +6.3%, ROCE holding at 11.1%. The read comes from the last 12 quarters of growth (revenue growth +2.2% latest, profit growth +6.3% latest, eps growth +6.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Relaxo Footwears Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 6 of stage 2), trading −13.6% versus its 200-day average and at 40% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Relaxo Footwears Ltd beating the market?
Not lately — on a trailing-13-week view Relaxo Footwears Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-08-21), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +68% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Relaxo Footwears Ltd's share price go up?
This page publishes no price forecast for Relaxo Footwears Ltd. What it measures instead: the share price is ₹325, the price is in a confirmed uptrend 6 weeks in. Its P/E of 43.6× sits at the 5th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Relaxo Footwears Ltd?
Promoters hold 71.3% of Relaxo Footwears Ltd, foreign institutions 3.1%, domestic institutions 9.7% and the public 15.9% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Relaxo Footwears Ltd have too much debt?
No — Relaxo Footwears Ltd's debt-to-equity is 0.11, and operating profit covers the interest bill 16×. FY26 borrowings were ₹233 Cr against equity of ₹2,206 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Relaxo Footwears Ltd's capex?
Relaxo Footwears Ltd spent ₹685 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹221 Cr, with ₹97.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Relaxo Footwears Ltd's cash flow?
Relaxo Footwears Ltd generated ₹348 Cr of operating cash flow in FY26 and ₹127 Cr of free cash flow after ₹221 Cr of capital spending. Reported profit that year was ₹179 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Relaxo Footwears Ltd's profit real cash?
Yes — over the last 3 fiscal years, 180% of Relaxo Footwears Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹348 Cr against reported profit of ₹179 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Relaxo Footwears Ltd in its business cycle?
Relaxo Footwears Ltd's FY26 operating margin was 14.0%, against a 13-year band of 12.0%–21.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Relaxo Footwears Ltd story?
The sharpest disagreement: annual EPS moved +5.3% against a −33.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Relaxo Footwears Ltd a stock worth studying right now?
This is not investment advice. The machine read: Relaxo Footwears Ltd is coiled. The quarters are improving, yet the P/E sits at the 5th percentile of its own 11-year range — the business is moving before the market. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!